Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- ELISA [1]
- Immunocytochemistry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF1587 - Provider product page
- Provider
- R&D Systems
- Product name
- Human IL-28A/IFN-lambda 2 Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human IL-28A/IFN-lambda 2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 60% cross-reactivity with human IL-28B/IFN-lambda 3 is observed. In direct ELISAs, approximately 30% cross-reactivity with recombinant human IL-29 and less than 5% cross-reactivity with recombinant mouse IL-28 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q8IZJ0
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Interleukin-28A triggers wound healing migration of bladder cancer cells via NF-κB-mediated MMP-9 expression inducing the MAPK pathway.
Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects.
Lee SJ, Lim JH, Choi YH, Kim WJ, Moon SK
Cellular signalling 2012 Sep;24(9):1734-42
Cellular signalling 2012 Sep;24(9):1734-42
Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects.
Li Q, Kawamura K, Okamoto S, Fujie H, Numasaki M, Namba M, Nagata M, Shimada H, Kobayashi H, Tagawa M
British journal of cancer 2011 Oct 25;105(9):1302-12
British journal of cancer 2011 Oct 25;105(9):1302-12
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Human IL-28A/IFN-lambda 2 ELISA Standard Curve. Recombinant Human IL-28A/IFN-lambda 2 protein was serially diluted 2-fold and captured by Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB15872) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- IL-28A/IFN-lambda 2 in Human PBMCs. IL-28A/IFN-lambda 2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) treated with calcium ionomycin and PMA using Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- IL-28A/IFN-lambda 2 Inhibition of EMCV-induced Cytopathy and Neutralization by Human IL-28A/IFN-lambda 2 Antibody. Recombinant Human IL-28A/ IFN-lambda 2 (Catalog # 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND50 is typically 0.3-1.5 µg/mL.